SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Renovis RNVS
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
45 9 0 RNVS
Emcee:  mopgcw Type:  Unmoderated
Introduction Market Data Compact
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
20GS: RNVS(IL/N): Awaiting PIII data on Cerovive in Q2/05. PII data on pain drug emopgcw-5/2/2005
19Astra stroke drug sales could hit $2 bln-Deutsche Fri Apr 1, 2005 06:29 AM ET nigel bates-4/1/2005
18Renovis Announces Results of Phase II Study of REN-1654 for the Treatment of Poskeokalani'nui-3/7/2005
17Renovis, Inc. Files Shelf Registration Statement Friday February 11, 5:40 pm ET mopgcw-2/22/2005
16as much as i wish this would work... Renovis Announces Initiation of Phase Ia Cmopgcw-2/22/2005
15Renovis Reports Fourth Quarter and Full Year 2004 Financial Results Thursday Febmopgcw-2/22/2005
14gs: RNVS(IL/N): Cerovive on track for filing in 2006. PII data on pain drug in Qmopgcw-2/22/2005
13Renovis Announces Completion of Enrollment in Phase II Trial of REN-1654 in Postscaram(o)uche-2/1/2005
12GS: RNVS (IL/N): Positive interim analysis of Cerovive in stroke 10/14/04 52-mopgcw-10/31/2004
11GS: RNVS(IL/N): Cerovive on track for filing in 2006. Pain program lags 52-Weekmopgcw-10/31/2004
10Phase III Trials for CEROVIVE (NXY-059) Will Continue as Planned Following Internigel bates-10/14/2004
9GS: 7. Renovis (RNVS, In-Line): Based on spending trends, we have raised our 200mopgcw-10/12/2004
8Renovis Reports Second Quarter 2004 Financial Results Thursday July 29, 4:00 pm mopgcw-9/6/2004
7GS Conference: RNVS (IL/N)- Interim efficacy analysis of Cerovive for stroke in mopgcw-6/14/2004
6GS: RNVS(IL/N):Cerovive passed 1st safety analysis. REN-213 neg in abdominal surmopgcw-4/29/2004
5Renovis Reports First Quarter 2004 Financial Results Tuesday April 27, 4:01 pm Emopgcw-4/29/2004
4From Forbes: Brain Repair Robert Langreth, 03.29.04 Biotech firms bet againstmopgcw-3/30/2004
3GS: Renovis, Inc. EPS (FY Dec) 2004E ($1.30), 2005E ($0.56) In-Line/Neutral (RNVmopgcw-3/28/2004
2See nitrone.com for more on Renovis, Cerovive, Astrazeneca and stroke. A nod toPeter H. Proctor-3/26/2004
1GS: RNVS(IL/N): Initiate coverage- poised to build sustainable pipeline in neuromopgcw-3/18/2004
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News